CAN04 development

A dual effect on cancer

Cantargia's CAN04 antibody treatment fights cancer by activating the immune system's killer cells and by blocking signals that lead to tumour growth. The target molecule, IL1RAP, is expressed in most common types of cancer, indicating a great potential of CAN04.


Preclinical development

Preclinical data has shown that IL1RAP is overexpressed by tumour cells from several different types of cancer. Furthermore, preclinical results show that a large number of cancer forms may be sensitive to CAN04 treatment. Additional studies are now being conducted to obtain additional documentation of CAN04 prior to clinical studies. CAN04 works both by decreasing the tumour inflammation and by stimulating the immune system’s killer cells to eradicate the tumour cells. Effects of CAN04 on tumour development and on the immune system are being studied in different cancer models. These studies include combination therapies. 

CAN04 is also documented from a safety perspective. Initial studies using treatment with repeat doses of up to 100 mg/kg proved very safe. A concluding GLP (Good Laboratory Practice) toxicity study is in the process of being initiated. 

Clinical development

Clinical development will initially focus on non-small cell lung cancer (NSCLC) and pancreatic cancer. The first part of the phase I/IIa study will evaluate safety and tolerability of CAN04 at escalating dose levels, while the second part has been designed to obtain an initial indication of anti-tumour activity in the chosen types of cancer. CAN04 therapy will be investigated both as monotherapy as well as in combination therapy. One further study is also planned to be conducted, which will look into mechanism of action and biomarkers during treatment of acute myeloid leukaemia (AML).

Manufacturing

CAN04 is manufactured in a biological production system. A specific cell-line licensed from BioWa Inc. in the USA enables us to produce antibodies with a more potent ADCC (Antibody-dependent Cellular Cytotoxicity) activity. More information about this technology can be found at www.biowa.com. The industrial manufacturing process is being developed by our partner, Glycotope Biotechnology GmbH, who manufactures the product for use in pre-clinical and clinical trials. CAN04 is produced in cells cultivated in up to a 1000 litre scale and is then purified in several steps to obtain a final product with high purity. Read more at www.glycotope.com



abild01.jpg#asset:384

abild0sa.jpg#asset:501

If you have any questions or concerns please do not hesitate to contact us.

Contact us